INTRODUCTION
The structures, mechanisms of action and resistance, and spectra of activity of the fluoroquinolones in vitro were considered in the first part of our two-part minireview (48) . To place this foregoing information in clinical perspective, we now discuss in this the second part of the minireview the published English literature on the pharmacology, proved and potential clinical uses, and toxicities of the fluoroquinolones in humans. HUMAN PHARMACOLOGY OF THE FLUOROQUINOLONES The pharmacologic properties of the fluoroquinolones have in general been determined in healthy human volunteers. After oral administration these agents were rapidly, although variably, absorbed, with peak serum concentrations attained within 2 h. Food has been shown to delay the absorption of ciprofloxacin (26) . Single oral doses of 400 to 600 mg of each of the fluoroquinolones considered resulted in peak serum levels (Cmax) above 1 ,ug/ml (and thus above the MIC for many organisms). Norfloxacin (1, 6, 38) and ciprofloxacin (7, 9, 17) appeared to have the lowest peak serum levels; pefloxacin (4, 32) and enoxacin (44) (21, 45 ). In contrast, the drugs producing higher serum levels had either little difference in Cmax and AUC values when intravenous and oral routes of administration were compared (pefloxacin [4] ) or had high urinary recoveries of drug given orally (enoxacin [43, 44, 46] , ofloxacin [29] ). Those fluoroquinolones with the lowest peak serum levels also have been reported to have high drug concentrations in stool (773 ,ug/g for norfloxacin [15] and 891 ± 624 ,ug/g for ciprofloxacin [7] ), but the extent to which biliary excretion might have contributed to stool concentrations was not determined directly. Taken (4, 46) . Relative to single-dose studies, certain of the fluoroquinolones given in multiple doses produced either moderate increases in the peak serum drug concentration (41 to 86% for enoxacin and ciprofloxacin [7, 46] ) associated with increases in the serum half-life or no change in these pharmacokinetic parameters (norfloxacin [42] ).
Drug binding to human serum proteins observed in vitro has been relatively low for each of the fluoroquinolones studied (14 to 30% [32, 38, 43, 45] ).
The terminal serum half-life (t1/2) of the fluoroquinolones was relatively long, ranging from 3 to 4 h for norfloxacin (1) and ciprofloxacin (2, 7, 9, 17 ) to 6 to 7 h for enoxacin (44) and ofloxacin (29) to 10 to 11 h for pefloxacin (4, 32) .
The fluoroquinolones were, in part, excreted by the kidneys. Twenty-four-hour urinary recovery of drug given orally varied among these compounds from 11% for pefloxacin to 73% for ofloxacin. Peak urinary concentrations (100 to 650 ,ug/ml) of the fluoroquinolones markedly exceeded their MICs for virtually all bacterial urinary tract pathogens, even accounting for the increases in MIC caused by the presence of urine and lowered pH (48) . In addition, in the presence of severe renal failure (glomerular filtration rate, <10 ml/min), urinary norfloxacin concentrations after a 400-mg dose (20 to 25 ,ug/ml) remained above the MIC for most pathogens (12) . When the glomerular filtration rate fell below 30 ml/min, the t1/2 of norfloxacin was prolonged (12, 13) . In the absence of renal failure, the renal clearance of norfloxacin (37, 38) , enoxacin (46) (37) . Renal clearance of pefloxacin was only 12 to 15% of normal glomerular filtration rate (4) .
The fluoroquinolones appear to differ in the extent to which nonrenal mechanisms contribute to drug elimination. For each of the three fluoroquinolones for which data are available, total body clearances exceeded renal clearances.
The ratio of total clearance to renal clearance was similar for enoxacin and ciprofloxacin (1.6 to 1.7 [21, 46] ) and considerably higher for pefloxacin (5.9 to 9.7 [4] ). The high urinary recovery of unchanged ofloxacin (29) suggests that nonrenal mechanisms account for no greater than 20 to 30% of its elimination, at least when renal function is normal. Total biliary excretion of the fluoroquinolones has not been determined in humans, but biliary concentrations of 5 ,ug of norfloxacin per ml after a single 200-mg dose (42) and 20 ,ug of pefloxacin per ml after a single 800-mg dose (32) have been reported. An enterohepatic circulation of ciprofloxacin has been suggested by increases in serum concentrations of the drug 2 to 4 h after an intravenous infusion in some subjects (21) . Drug metabolism appears to occur to the greatest extent with pefloxacin and to a lesser extent with the other fluoroquinolones studied. Published data, however, are scant. Most alterations occurred in the piperazine ring and have included demethylation of the 4' nitrogen (pefloxacin [32] ), formation of a 5' carbonyl group (norfloxacin, pefloxacin, enoxacin, and ciprofloxacin [17, 32, 42, 44] ), formation of a 4' N-oxide (pefloxacin [32] ), and opening of the piperazine ring to form a 7-ethylenediamine derivative (norfloxacin and ciprofloxacin [17, 42] ). A glucuronide conjugate has been identified as a minor metabolite of pefloxacin (32) . The concentration of metabolites of perfloxacin exceeded that of the parent compound in serum and urine; the major demethyl metabolite was norfloxacin which has substantial antibacterial activity (32) . Most of the other metabolites of pefloxacin and other fluoroquinolones had, in contrast, less antibacterial activity than their parent compounds. For norfloxacin, enoxacin, and ciprofloxacin, metabolites constituted from 15 to 30% of the drug recoverable in the urine (17, 21, 24, 26, 42, 44) ; of these three, only for enoxacin have metabolites been detected in serum, albeit at low levels (10%). There are as yet no published data on the specific metabolites of ofloxacin, although they are likely to constitute <20% of drug excreted. For ciprofloxacin the ratio of drug metabolites to total unchanged drug plus metabolites in urine increased by 44% when the drug was given orally rather than intravenously, suggesting some degree of firstpass hepatic metabolism when ciprofloxacin is given by the oral route (21) . Data from individual subjects given norfloxacin have also been considered to support first-pass metabolism of this fluoroquinolone (42) .
Certain structural correlations are suggested by the comparison of the pharmacokinetics of the fluoroquinolones. These comparisons, however, must be interpreted with caution, because they are not direct, and the results might vary with the different groups of test subjects and with the presumably different oral drug formulations used. Norfloxacin and ciprofloxacin were similar in their values for Cmax, AUC, t1/2, and urinary recovery, suggesting that substitution of a cyclopropyl for an ethyl moiety at the 1-nitrogen position is insufficient to affect these parameters. In contrast, the addition of a methyl group to the 4' nitrogen of the piperazine ring of norfloxacin (creating pefloxacin) or the substitution of a nitrogen for a carbon at the 8 position of norfloxacin (creating enoxacin) might account for increases in Cma,x, AUC, and t12. Finally, the extensive demethylation of the piperazine ring of pefloxacin when given to humans appears not to occur with ofloxacin, which contains a ring structure rather than an ethyl substituent at the 1-nitrogen position.
All of the fluoroquinolones studied appear to distribute widely in bodily fluids. Volumes of distribution (Vd) were high for pefloxacin (Vd = 65 liters) (4) and ciprofloxacin (Vd = 177 liters) (45) given intravenously. In the latter case a value substantially greater than that of total body water strongly suggests that the drug is concentrated in certain tissues. Drug concentrations in the inflammatory exudate within experimentally induced blisters have ranged from 1 to 5 ptg/ml (Table 1) . Comparisons in the same laboratory of the ratio of AUC values for serum and blister fluid for norfloxacin, enoxacin, ciprofloxacin, and ofloxacin suggest approximately equivalent, excellent drug penetration (1, 9, 29, 44 17), and peak enoxacin concentrations in sputa from patients with acute exacerbations of chronic bronchitis were 90% of peak serum concentrations (10) . In the presence of meningeal inflammation, pefloxacin appears to penetrate well into the cerebrospinal fluid, reaching concentrations of 4.8 ± 0.79 ,ug/ml (44% that of serum) (47) . Similar drug penetration into cerebrospinal fluid was also seen when pefloxacin was given after the recovery of patients from meningitis (47 [34] [35] [36] 40) . Norfloxacin, when given with one exception (14) in doses of 400 mg orally twice daily, demonstratqd significantly higher (35, 36) or equivalent rates of cure when compared in eight randomized, nonblinded studies to orally administered trimethoprim-sulfamethoxazole (14, 16, 18, 19, 36, 40) , amoxicillin (28) , or nalidixic acid (35) ( Table 2 ). When specified (eight studies), most studies included only patients with uncomplicated infections (absence of catheters, structural defects in the urinary tract, or abnormal renal function) (11, 14, 16, 19, 25, (34) (35) (36) . In the two studies that included complicated infections (catheterized patients, some elderly with mild degrees of azotemia), 84 to 95% of the patients were reported cured (27, 28) . In the one comparative study, norfloxacin cured 19 of 20 patients (95%), and amoxicillin cured 15 of 20 patients (75%) (P = 0.08, Fisher's exact test) (28) . In three other studies (18, 34, 36) , a small number of patients with antibody-coated bacteria in the urine, suggesting pyelonephritis, were also cured. In most instances the infecting organisms were Escherichia coli or other enteric gram-negative bacilli, but lesser numbers of urinary tract infections caused by Pseudomonas aeruginosa were also successfully treated (22 of 25 from three studies) (19, 27, 34) . Among nine studies which assessed bacterial susceptibilities after treatment of 397 infected patients with norfloxacin (11, 14, 16, 18, 19, 27, 28, 34, 40) , therapeutic failures were associated with the appearance of norfloxacin-resistant organisms in only four individuals (1.0%). These four cases included two reinfections, one with Streptococcus faecalis (11) and one with a group B streptococcus (16) , one relapse with P. aeruginosa (27) , and one relapse with E. coli having an MIC of 1 pug of norfloxacin per ml (28) , a drug concentration still substantially. below that attainable in urine. Thus, the development of resistance to norfloxacin during treatment of urinary tract infections has been to date an infrequent event. Analysis of other factors associated with therapeutic failures were not reported in most studies. In one small study relapse tended to occur in patients with antibody-coated bacteria in the urine (P = 0.09, Fisher's exact test) (18) , but a multiclinic study with larger 718 MINIREVIEW on November 6, 2017 by guest http://aac.asm.org/ Downloaded from numbers of patients found no difference in bacteriologic outcome between groups of patients with or without antibody-coated bacteria in the urine (36) . Norfloxacin was recently found to be equivalent to or better than trimethoprim-sulfamethoxazole in eliminating periurethral and anal colonization with urinary tract pathogens, suggesting potential use for norfloxacin in prophylaxis of recurrent urinary tract infections (19) .
Norfloxacin, given as two 600-mg doses 4 h apart, also appears to be highly effective and equivalent to spectinomycin (2 gm intramuscularly) in curing uncomplicated gonococcal urethritis in men (8) , including infections caused by 3-lactamase-producing strains of Neisseriia gonorrhoeae.
Two cases of gonococcal pharyngitis were also successfully treated. A similar efficacy was found when enoxacin (given orally as a single 600-mg dose or two 400-mg doses 4 h apart) was used to treat uncomplicated gonococcal urethritis and cervicitis (33) . Good tissue penetration (including the prostate) and urinary drug concentrations substantially above the MIC for Chiamydia tirachomatis and Ureaplasma lureaalyticulm (48) suggest the possibility of concurrent treatment of nongonococcal urethritis. Enoxacin therapy of gonococcal urethritis (in the doses and for the brief duration specified above), however, was followed in 32% of cases by postgonococcal urethritis (33) . No data on the activity of the fluoroquinolones against Treponemra pallidlon are yet available.
The antimicrobial activity and pharmacology of the fluoroquinolones suggest potential clinical uses in addition to treatment of urinary tract infections and gonorrhea. In general, the fluoroquinolones might be considered in bacterial infections in patients for whom use of other drugs such as r-lactams or aminoglycosides is contraindicated and in infections with multiply resistant bacteria. Specific additional uses might include treatment of: (i) prostatitis; (ii) severe gastroenteritis likely to be of bacterial etiology before identification of a pathogen; (iii) selective decontamination of the gastrointestinal tract (i.e., maintaining the anaerobic flora for colonization resistance) of neutropenic patients, using fluoroquinolones such as norfloxacin which have high stool concentrations, have little activity against anerobic bacteria, and have activity against P. aeruiginosa and enteric gram-negative bacilli; (iv) pneumonia caused by gramnegative bacilli when oral therapy is desirable; (v) upper respiratory tract colonization with methicillin-resistant Staphylococcus aureius when indicated; (vi) serious infections caused by methicillin-resistant staphylococci when vancomycin cannot be used; and (vii) gram-negative bacillary osteomyelitis. The availability of parenteral preparations of the fluoroquinolones might, in addition, allow treatment of more acutely ill patients unable to take medication by mouth. Once clinical improvement ensued, use of the oral formulation would provide the possibility of completion of therapy as an outpatient. The foregoing speculative uses, however, must await proof of efficacy from ongoing and future studies.
TOXICITIES OF THE FLUOROQUINOLONES IN HUMANS
Published data on the adverse effects of the fluoroquinolones are limited to the previously cited studies, generally using norfloxacin or enoxacin at doses of 400 mg twice daily for 3 to 14 days. In each comparative study the adverse effects reported with norfloxacin were similar to (14, 16, 18, 19, 28, (34) (35) (36) 40) (11, 14, 16, 18, 19, 25, 27, 28, (34) (35) (36) 40) . Gastrointestinal symptoms (nausea, vomiting, anorexia) and central nervous system symptoms (lightheadedness, headache, drowsiness, insomnia) were the most frequently reported but rarely were severe or required cessation of therapy. Four patients had joint swelling or tendonitis (three involving fingers) (3, 11, 25) , two of whom had recurrences upon rechallenge with norfloxacin. Either a low frequency (1.6%) (36) or no abnormalities of laboratory tests (blood counts and liver function tests) (11, 16, 19, 25, 27, 34) were found in most studies. In one study equivalent higher frequencies of laboratory abnormalities were found both in patients receiving norfloxacin and in those receiving trimethoprim-sulfamethoxazole (18) .
Enoxacin given in doses similar to that of norfloxacin (400 mg twice daily for 14 days) in one study had similar low frequencies of adverse reactions (39) . In two other studies, however, toxicities were reported to be more frequent (10, 46) . Interpretation of these results, however, is complicated by the high frequency of toxicities reported by the placebotreated patients in one study (46) and by the concurrent administration of theophylline in the other (10) . Enoxacin therapy has been associated with impaired excretion and toxic serum levels of theophylline (30, 41) .
Thus, the adverse effects of norfloxacin given in the doses specified for short periods of time appear to be acceptably low. The side effects of enoxacin will require further study. Determination of toxicities associated with the use of the other fluoroquinolones and of higher doses and longer duration of therapy with norfloxacin must also await additional studies. Additional potential toxicities include: (i) the development of crystalluria with use of high doses of fluoroquinolones, as has been seen after administration of norfloxacin in doses of 1,200 to 1,600 mg (38) : (ii) central nervous system toxicities, as were previously seen uncommonly with nalidixic acid (pseudotumor cerebri, confusion, and seizures) (31) and more frequently with rosoxacin (dizziness) (20) ; and (iii) cartilage toxicity, as has been seen in some animals treated with nalidixic acid. Until bone and cartilage toxicities have been shown not to occur in humans, it would seem prudent that the fluroroquinolones not be used routinely in patients whose skeletal growth is incomplete.
CONCLUSION
In the next several years, studies will define further the efficacy of the fluoroquinolones, reveal the toxicities to humans, and establish whether emergence of bacterial resistance or overgrowth with intrinsically resistant organisms will be major clinical problems. The foregoing sections appear to provide a basis for cautious optimism that these bactericidal, broad-spectrum, orally adminstered agents will be able to fill effectively specific therapeutic needs only partially or poorly filled by currently available agents.
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